再鼎医药一季度总收入1.06亿美元 同比增加22.19%

金融界
09 May

再鼎医药发布截至2025年3月31日止三个月的未经审计业绩,总收入1.06亿美元,同比增加22.19%;研发开支6072.9万美元,同比增加11.13%。

其中,2025年第一季度产品收入净额为1.057亿美元,2024年同期为8710万美元,同比增长 21%,按固定汇率计算同比增长23%。这一增长主要是由卫伟迦、则乐和纽再乐销售额增长所驱动。

责任编辑:栎树

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10